Protagonist Therapeutics, Inc. Stock price
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.93 USD | +1.58% | +2.05% | +26.17% |
Financials (USD)
Sales 2024 * | 208M | Sales 2025 * | 120M | Capitalization | 1.69B |
---|---|---|---|---|---|
Net income 2024 * | 24M | Net income 2025 * | -6M | EV / Sales 2024 * | 6.26 x |
Net cash position 2024 * | 388M | Net cash position 2025 * | 637M | EV / Sales 2025 * | 8.75 x |
P/E ratio 2024 * |
79.7
x | P/E ratio 2025 * |
-35.7
x | Employees | 112 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.48% |
Latest transcript on Protagonist Therapeutics, Inc.
1 day | +1.58% | ||
1 week | +2.05% | ||
Current month | -4.77% | ||
1 month | -4.93% | ||
3 months | +25.08% | ||
6 months | +68.88% | ||
Current year | +26.17% |
Managers | Title | Age | Since |
---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 67 | 08-11-30 |
Asif Ali
DFI | Director of Finance/CFO | 50 | 22-04-17 |
Chief Tech/Sci/R&D Officer | - | 17-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Williams
BRD | Director/Board Member | 74 | 17-06-07 |
Harold Selick
CHM | Chairman | 69 | 09-01-31 |
Daniel Swisher
BRD | Director/Board Member | 61 | 23-10-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 2 M€ | -.--% | ||
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 28.93 | +1.58% | 653,366 |
24-03-27 | 28.48 | +1.71% | 359,436 |
24-03-26 | 28 | +0.39% | 307,470 |
24-03-25 | 27.89 | -0.50% | 247,394 |
24-03-22 | 28.03 | -1.13% | 376,485 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.17% | 1.69B | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |